Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
Five years ago, we reported the identification and characterization of several regulatory T-cell epitopes (now called Tregitopes) that were discovered in the heavy and light chains of IgG (De Groot et al. Blood, 2008). When added ex vivo to human PBMCs, these Tregitopes activated regulatory T cells...
Saved in:
| Main Authors: | Anne S. De Groot, Leslie Cousens, Federico Mingozzi, William Martin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/493138 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The effects of glucocorticoid plus intravenous immunoglobulin (IVIG) vs IVIG alone on platelet activation in children with Kawasaki disease
by: Qiong-Qiong Wang, et al.
Published: (2023-08-01) -
Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
by: Zhouping Wang, et al.
Published: (2020-01-01) -
An improved procedure for synthesis of lenalidomide as an active pharmaceutical ingredient
by: Elaheh Ataollahi, et al.
Published: (2025-09-01) -
WCN25-4208 COMPARATIVE OUTCOMES OF IVIG MONOTHERAPY VERSUS PLASMAPHERESIS-COMBINED IVIG IN CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION
by: Nayan Poddar, et al.
Published: (2025-02-01) -
Malignancy in neuromuscular patients on chronic IVIG
by: Mohamed Khateb, et al.
Published: (2025-06-01)